Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.

Disclosure: The author does not hold a position in NTLA.

← Back to Free Index

NTLA

Analysis as of: 2026-01-28

Intellia Therapeutics, Inc.

Clinical-stage biotechnology company developing CRISPR/Cas9-based gene-editing therapies, led by late-stage in vivo programs in hereditary angioedema and transthyretin amyloidosis.

biotech healthcare

On Yahoo Finance ...

Jump to: Summary • Analysis • Opportunity • Risk • Trends • Third Party Analyst Consensus

Summary

Phase 3 data could reset one-time prophylaxis credibility

The next 6–12 months are gating: a clean Phase 3 readout and credible filing path can unlock a commercial rerate, while safety/monitoring friction or payer pushback can keep valuation anchored.

Analysis

Thesis

If lonvo-z’s Phase 3 readout is clean and durable, NTLA can transition from “platform + safety overhang” to a commercial rare-disease franchise: one-time prophylaxis plus a payer/center network and safety-evidence moat that accelerates uptake and supports premium economics; ATTR is upside optionality if regulators regain confidence.

Last Economy Alignment

Winner traits are trust, verification, and velocity: outcomes data loops, payer contracting rails, and AI-accelerated design/safety workflows can compound across programs.

Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple

11.4x (from 5 most recent analyses)

Reasoning

The 5-year rerate is driven by a single non-linear step: credible Phase 3 proof that one infusion can prevent attacks durably enough to justify “switching” patients off chronic prophylaxis. If validated, the company can build hard-to-copy distribution (centers + payer contracts + longitudinal safety evidence), turning a one-product launch into a repeatable commercialization playbook and keeping platform optionality alive despite ATTR hold uncertainty.

Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary

The dominant risk is regulatory trust in systemic in vivo editing after liver-safety events: it can extend holds, force restrictive protocols, and slow adoption. Second is commercial conversion risk—payers and centers must operationalize one-time economics and long-term monitoring. Third is financing: without a fast launch ramp, dilution can meaningfully cap per-share upside even if science works.

Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Trends

Key Changes

2026-01-27: FDA lifted the clinical hold on the MAGNITUDE-2 Phase 3 trial (ATTRv-PN), enabling restart activities under enhanced liver monitoring.
ATTR-CM MAGNITUDE trial remains on clinical hold; timing and restart conditions are still uncertain.
Near-term repricing surface has shifted toward “execution proof” (restart confirmation) ahead of efficacy readouts.

Thesis update

Thesis is directionally similar; updated to reflect MAGNITUDE-2 hold lift while keeping ATTR-CM as unresolved overhang.

Forecast update

Moved more conservative on 5-year revenue ramp and terminal multiple to reflect monitoring/permissioning friction and dilution risk despite the near-term regulatory positive.

Upgrade to Builder to also access: Future Considerations

Third Party Analyst Consensus

12-Month Price Target

$17.72

Upgrade to Reader to also access: Bull Case, Base Case, Bear Case